MCID: CCN001
MIFTS: 47

Cocaine Dependence

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cocaine Dependence

Summaries for Cocaine Dependence

Disease Ontology: 11 A drug dependence that is a psychological dependency on the regular use of cocaine.

MalaCards based summary: Cocaine Dependence is related to polysubstance abuse and personality disorder. An important gene associated with Cocaine Dependence is DRD2 (Dopamine Receptor D2), and among its related pathways/superpathways are Transmission across Chemical Synapses and Postsynaptic nicotinic acetylcholine receptors. The drugs Caffeine and Lamotrigine have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cortex, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: 75 Cocaine dependence is a neurological disorder that is characterized by withdrawal symptoms upon... more...

Related Diseases for Cocaine Dependence

Diseases related to Cocaine Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 polysubstance abuse 31.1 DRD3 DRD2
2 personality disorder 30.9 SLC6A4 SLC6A3 PRL DRD3 DRD2 ANKK1
3 post-traumatic stress disorder 30.7 SLC6A4 SLC6A3 POMC MIR124-1 DRD2
4 cannabis dependence 30.7 GABRA2 DRD2 ANKK1
5 bipolar i disorder 30.6 SLC6A4 PRL DRD2
6 alcohol use disorder 30.6 SLC6A4 SLC6A3 POMC PDYN OPRM1 GABRA2
7 opiate dependence 30.6 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
8 cocaine abuse 30.6 SLC6A4 SLC6A3 SLC18A2 PDYN OPRM1 OPRK1
9 dopamine beta-hydroxylase deficiency 30.6 SLC18A2 DBH
10 psychotic disorder 30.5 SLC6A4 SLC6A3 SLC18A2 PRL PDYN OPRM1
11 acute stress disorder 30.5 SLC6A4 POMC
12 heroin dependence 30.4 SLC6A4 SLC6A3 PDYN OPRM1 DRD3 DRD2
13 borderline personality disorder 30.4 SLC6A4 SLC6A3 PRL DRD2
14 bulimia nervosa 30.3 SLC6A4 SLC6A3 DRD2
15 antisocial personality disorder 30.3 SLC6A4 SLC6A3 PRL LOC110806262 GABRA2 DRD2
16 cannabis abuse 30.2 SLC6A4 DRD2 ANKK1
17 pathological gambling 30.2 SLC6A4 SLC6A3 PDYN OPRM1 DRD3 DRD2
18 substance abuse 30.2 SLC6A4 SLC6A3 PRL POMC PDYN OPRM1
19 schizoaffective disorder 30.2 SLC6A4 PRL DRD3 DRD2
20 toxic encephalopathy 30.1 SLC6A3 SLC18A2 MIR124-1
21 withdrawal disorder 30.1 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
22 movement disease 30.1 SLC6A3 SLC18A2 DRD3 DRD2
23 narcolepsy 30.1 SLC6A3 SLC18A2 PDYN DRD2
24 sleep disorder 30.1 SLC6A4 SLC6A3 SLC18A2 POMC
25 bipolar disorder 30.1 SLC6A4 SLC6A3 SLC18A2 PRL PDYN OPRM1
26 endogenous depression 30.0 SLC6A4 SLC6A3 PRL POMC DRD2
27 opioid abuse 30.0 POMC PDYN OPRM1 OPRK1 DRD2
28 major depressive disorder 29.9 SLC6A4 SLC6A3 SLC18A2 PRL POMC PDYN
29 mood disorder 29.8 SLC6A4 SLC6A3 SLC18A2 POMC PDYN MIR124-1
30 dystonia 29.8 SLC6A3 SLC18A2 PRL PDYN DRD3 DRD2
31 attention deficit-hyperactivity disorder 29.7 SLC6A4 SLC6A3 SLC18A2 POMC PDYN OPRM1
32 alcohol dependence 29.6 SLC6A4 SLC6A3 SLC18A2 POMC PDYN OPRM1
33 drug dependence 29.5 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
34 substance dependence 29.4 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
35 schizophrenia 29.3 SLC6A4 SLC6A3 SLC18A2 PRL POMC PDYN
36 anxiety 29.3 SLC6A4 SLC6A3 PRL POMC PDYN OPRM1
37 tobacco addiction 29.2 SLC6A4 SLC6A3 PDYN OPRM1 GABRA2 DRD3
38 galactorrhea 10.4 PRL DRD2
39 alcoholic psychosis 10.4 SLC6A4 DRD2
40 paraphilia disorder 10.4 SLC6A4 DRD2
41 chiasmal syndrome 10.4 PRL POMC
42 obsessive-compulsive personality disorder 10.4 SLC6A4 DRD3
43 tuberculum sellae meningioma 10.4 PRL POMC
44 cyclothymic disorder 10.4 SLC6A4 DRD2
45 avoidant personality disorder 10.4 SLC6A4 SLC6A3
46 tardive dyskinesia 10.4 DRD2 DBH
47 sella turcica neoplasm 10.4 PRL POMC
48 acidophil adenoma 10.4 PRL POMC
49 mixed cerebral palsy 10.4 SLC6A3 PRL
50 chromophobe adenoma 10.4 PRL POMC

Graphical network of the top 20 diseases related to Cocaine Dependence:



Diseases related to Cocaine Dependence

Symptoms & Phenotypes for Cocaine Dependence

MGI Mouse Phenotypes related to Cocaine Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.3 CHRNA5 CHRNA6 CHRNB4 DBH DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.1 CHRNB4 DBH DRD2 DRD3 FAM53B GABRA2
3 adipose tissue MP:0005375 9.87 DBH DRD2 DRD3 GABRA2 OPRM1 PDYN
4 behavior/neurological MP:0005386 9.86 CHRNA5 CHRNB3 CHRNB4 DBH DRD2 DRD3
5 digestive/alimentary MP:0005381 9.76 CHRNB4 DRD2 DRD3 OPRK1 OPRM1 PDYN
6 integument MP:0010771 9.4 CHRNA5 CHRNB4 DBH DRD2 GABRA2 OPRK1

Drugs & Therapeutics for Cocaine Dependence

Drugs for Cocaine Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
3
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 4 8002-43-5, 1446756-47-3, 18656-38-7 26197 9547096 6323481
4
Choline Approved, Nutraceutical Phase 4 62-49-7 305
5 Phosphodiesterase Inhibitors Phase 4
6 Antidepressive Agents Phase 4
7 Sodium Channel Blockers Phase 4
8 Diuretics, Potassium Sparing Phase 4
9
Quetiapine Fumarate Phase 4 111974-72-2
10 Calcium, Dietary Phase 4
11 calcium channel blockers Phase 4
12 Antimetabolites Phase 4
13 Hypolipidemic Agents Phase 4
14 Lipid Regulating Agents Phase 4
15 Cytidine Diphosphate Choline Phase 4
16
Calcium Nutraceutical Phase 4 7440-70-2 271
17
Oxytocin Approved, Vet_approved Phase 2, Phase 3 50-56-6 439302 53477758
18
Bupropion Approved Phase 2, Phase 3 31677-93-7, 34841-39-9, 34911-55-2 444
19
Citalopram Approved Phase 2, Phase 3 59729-32-7, 59729-33-8 2771
20
Biperiden Approved, Investigational Phase 3 514-65-8 2381
21
Topiramate Approved Phase 2, Phase 3 97240-79-4 5284627
22
Mirtazapine Approved Phase 2, Phase 3 85650-52-8, 61337-67-5 4205
23
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359 38101
24
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
25
Pergolide Approved, Investigational, Vet_approved, Withdrawn Phase 3 66104-22-1 47811
26
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9, 14611-52-0 5195 26757
27
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
28
Nicotine Approved Phase 3 54-11-5 942 89594
29
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 52485-79-7, 53152-21-9 644073 40400
30
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
31
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
32
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2 30843
33
1,2-Dihydroxybenzene Experimental Phase 2, Phase 3 120-80-9 289
34 Adderall Phase 2, Phase 3
35 Serotonin Uptake Inhibitors Phase 2, Phase 3
36 Analgesics Phase 2, Phase 3
37 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
38 Parasympatholytics Phase 3
39 Antiparkinson Agents Phase 3
40 Muscarinic Antagonists Phase 3
41 Cholinergic Antagonists Phase 3
42 Narcotics Phase 2, Phase 3
43
Biperiden lactate Phase 3
44 Hypoglycemic Agents Phase 2, Phase 3
45 Narcotic Antagonists Phase 2, Phase 3
46 Monoamine Oxidase Inhibitors Phase 3
47 Adjuvants, Immunologic Phase 2, Phase 3
48 Pharmaceutical Solutions Phase 2, Phase 3
49 Immunologic Factors Phase 2, Phase 3
50 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 227)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
3 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
4 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
5 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
6 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
7 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Disorder Recruiting NCT02927236 Phase 4
8 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
9 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
10 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
11 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
12 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR
13 Bupropion-Enhanced CM for Cocaine Dependence Completed NCT02111798 Phase 2, Phase 3 Placebo;Bupropion XL
14 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
15 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
16 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
17 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
18 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
19 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
20 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
21 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
22 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Completed NCT02774954 Phase 3
23 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
24 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
25 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
26 Treatment of Adult ADHD in Methadone Patients Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
27 A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
28 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
29 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
30 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
31 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
32 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
33 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
34 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
35 Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
36 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
37 A Sequenced Behavioral and Medication Intervention for Cocaine Dependence Completed NCT01986075 Phase 1, Phase 2 Mixed-Amphetamine Salts- Extended Release (MAS-ER);Placebo
38 Sertraline Augmented With GABA Agents for Cocaine Dependence Completed NCT00654953 Phase 2 sertraline;Placebo;gabapentin
39 A Phase II, Double-Blind, Placebo-Controlled, Trial Of NS2359 For The Treatment of Cocaine Dependence Completed NCT02798627 Phase 2 NS2359;placebo
40 Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Nepicastat for Cocaine Dependence Completed NCT01704196 Phase 2 Nepicastat;Placebo
41 A Phase II, Randomized, Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence Completed NCT01680887 Phase 2 Varenicline;Placebo
42 Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence Completed NCT00733993 Phase 1, Phase 2 Caffeine 150 MG;Placebo;Amphetamine;Caffeine 300 MG
43 A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence Completed NCT00385268 Phase 2 acamprosate;placebo
44 Neural Substrates of Emotion: Impact of Cocaine Dependence Completed NCT02682784 Phase 2 Oxytocin;Placebo
45 Brain Function and Structure in Cocaine Dependence Completed NCT02080832 Phase 2 Citalopram;Placebo
46 Pharmacotherapy & CM for Opioid and Cocaine Dependence Completed NCT00838981 Phase 1, Phase 2 Modafinil;Sugar Pill;Methadone
47 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) and Topiramate for the Treatment of Cocaine Dependence Completed NCT00421603 Phase 2 Adderall-XR and Topiramate;Placebo
48 5-HT2AR: 5HT2CR Balance in Brain Connectivity in Cocaine Dependence Completed NCT03921151 Phase 1, Phase 2 Mirtazapine 15 MG Oral Tablet
49 PPARγ Agonist Treatment for Cocaine Dependence Completed NCT02774343 Phase 1, Phase 2 Pioglitazone;Placebo
50 Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence Completed NCT00713583 Phase 2 levodopa;Placebo

Search NIH Clinical Center for Cocaine Dependence

Genetic Tests for Cocaine Dependence

Anatomical Context for Cocaine Dependence

Organs/tissues related to Cocaine Dependence:

MalaCards : Brain, Prefrontal Cortex, Cortex, Pituitary, Amygdala, Temporal Lobe, Thalamus

Publications for Cocaine Dependence

Articles related to Cocaine Dependence:

(show top 50) (show all 1723)
# Title Authors PMID Year
1
Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. 53 62
20170711 2010
2
Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence. 53 62
19503018 2009
3
mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. 53 62
19720750 2009
4
Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. 53 62
19349312 2009
5
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. 53 62
18923396 2009
6
Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 53 62
18321529 2008
7
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? 53 62
15988468 2005
8
Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine-dependent individuals and healthy volunteers. 53 62
15091312 2004
9
Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability. 53 62
15545018 2004
10
Dopamine transporter as target for drug development of cocaine dependence medications. 53 62
14612141 2003
11
No association between polymorphisms in the serotonin transporter gene and susceptibility to cocaine dependence among African-American individuals. 53 62
12218660 2002
12
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. 53 62
11092766 2000
13
PET studies of brain monoamine transporters. 53 62
10974156 2000
14
Family-based study of DRD2 alleles in alcohol and drug dependence. 53 62
11054774 2000
15
Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. 53 62
10523822 1999
16
No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. 53 62
10023512 1999
17
Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence? 53 62
9154209 1997
18
No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. 53 62
12893467 1996
19
Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. 53 62
7865100 1994
20
Allelic association of the D2 dopamine receptor gene with cocaine dependence. 53 62
8261891 1993
21
Trends in cannabis or cocaine-related dependence and alcohol/drug treatment in Argentina, Chile, and Uruguay. 62
35939947 2022
22
Effects of Human Immunodeficiency Virus Infection and Former Cocaine Dependence on Neuroanatomical Measures and Neurocognitive Performance. 62
35963584 2022
23
Are Borderline Personality Disorder Features Differentially Related to Pre-Incarceration Alcohol, Cannabis, Cocaine, and Opioid Dependence Among People Recently Incarcerated in Jail? 62
36181491 2022
24
Disrupted dynamic interactions between large-scale brain networks in cocaine users are associated with dependence severity. 62
36064187 2022
25
Correlates of cannabis use disorder in the United States: A comparison of logistic regression, classification trees, and random forests. 62
35636037 2022
26
Development of a Highly Efficient Long-Acting Cocaine Hydrolase Entity to Accelerate Cocaine Metabolism. 62
35767675 2022
27
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. 62
35218405 2022
28
Bayesian set of best dynamic treatment regimes: Construction and sample size calculation for SMARTs with binary outcomes. 62
35124836 2022
29
Machine Learning Analysis of Cocaine Addiction Informed by DAT, SERT, and NET-Based Interactome Networks. 62
35294204 2022
30
Impaired verbal memory in individuals living with HIV and cocaine dependence. 62
35786160 2022
31
Modafinil Does Not Reduce Cocaine Use in Methadone-Maintained Individuals. 62
36310662 2022
32
Varenicline for the Treatment of Cocaine Dependence. 62
33840773 2022
33
The GLT-1 enhancer clavulanic acid suppresses cocaine place preference behavior and reduces GCPII activity and protein levels in the rat nucleus accumbens. 62
35051699 2022
34
Occurrence and severity of cocaine-induced hallucinations: Two distinct phenotypes with shared clinical factors but specific genetic risk factors. 62
35124387 2022
35
Bidirectional influence of heroin and cocaine escalation in persons with dual opioid and cocaine dependence diagnoses. 62
33119382 2022
36
Assessing combinatorial effects of HIV infection and former cocaine dependence on cognitive control processes: A functional neuroimaging study of response inhibition. 62
34695441 2022
37
Mean corrected generalized estimating equations for longitudinal binary outcomes with report bias. 62
34931910 2022
38
Common and gender-specific associations with cocaine use on gray matter volume: Data from the ENIGMA addiction working group. 62
32857473 2022
39
Binge drinking in early adulthood: A machine learning approach. 62
34598011 2022
40
Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression. 62
36046837 2022
41
Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population. 62
34843875 2022
42
Recurrent noninfectious preseptal cellulitis secondary to cocaine use and levamisole-associated vasculitis. 62
35754587 2022
43
Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice. 62
34157334 2021
44
Proteome-Informed Machine Learning Studies of Cocaine Addiction. 62
34752088 2021
45
Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies. 62
34273801 2021
46
Methylation of the tyrosine hydroxylase gene is dysregulated by cocaine dependence in the human striatum. 62
34693223 2021
47
Early onset consumption of coca paste associated with executive-attention vulnerability markers linked to caudate-frontal structural and functional abnormalities. 62
34364191 2021
48
Hypericum perforatum L. prevents the acquisition of and promotes resilience against stress-induced reinstatement of the conditioned place preference induced by cocaine. 62
34371124 2021
49
Age of onset of heaviest use of cannabis or alcohol in persons with severe opioid or cocaine use disorders. 62
34216857 2021
50
Sex differences in behavioral traits related with high sensitivity to the reinforcing effects of cocaine. 62
34333071 2021

Variations for Cocaine Dependence

Expression for Cocaine Dependence

Search GEO for disease gene expression data for Cocaine Dependence.

Pathways for Cocaine Dependence

GO Terms for Cocaine Dependence

Cellular components related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.7 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DBH DRD2
2 membrane GO:0016021 10.7 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DBH DRD2
3 plasma membrane GO:0005886 10.58 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DRD2 DRD3
4 plasma membrane GO:0005887 10.58 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DRD2 DRD3
5 neuron projection GO:0043005 10.36 CHRNA5 CHRNA6 CHRNB3 CHRNB4 GABRA2 OPRK1
6 synapse GO:0045202 10.32 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DBH DRD2
7 axon terminus GO:0043679 10.08 DRD2 OPRK1 PDYN SLC6A3
8 acetylcholine-gated channel complex GO:0005892 10.06 CHRNB4 CHRNB3 CHRNA6 CHRNA5
9 synaptic vesicle membrane GO:0030672 9.99 SLC18A2 OPRK1 GABRA2 DRD2
10 presynaptic membrane GO:0042734 9.98 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2 CHRNA6
11 obsolete integral component of presynaptic membrane GO:0099056 9.73 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2 CHRNA6
12 dopaminergic synapse GO:0098691 9.73 SLC6A3 SLC18A2 DRD2 CHRNB3 CHRNA6 CHRNA5
13 obsolete integral component of postsynaptic membrane GO:0099055 9.63 CHRNA6 DRD2 OPRK1 OPRM1 SLC6A3 SLC6A4
14 postsynaptic membrane GO:0045211 9.47 SLC6A4 SLC6A3 OPRM1 OPRK1 GABRA2 DRD2

Biological processes related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.52 PRL POMC OPRM1 OPRK1 GABRA2 DRD3
2 monoatomic ion transmembrane transport GO:0034220 10.31 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
3 neuropeptide signaling pathway GO:0007218 10.24 POMC PDYN OPRM1 OPRK1
4 regulation of membrane potential GO:0042391 10.21 CHRNA5 CHRNA6 CHRNB3 CHRNB4 GABRA2
5 neurotransmitter transport GO:0006836 10.16 SLC6A4 SLC6A3 SLC18A2 GABRA2
6 visual learning GO:0008542 10.14 DRD3 DRD2 DBH
7 response to amphetamine GO:0001975 10.11 DBH DRD2 SLC18A2
8 regulation of dopamine secretion GO:0014059 10.11 DRD3 DRD2 CHRNA6
9 nervous system process GO:0050877 10.1 CHRNA5 CHRNA6 CHRNB3 CHRNB4 GABRA2
10 response to ethanol GO:0045471 10.09 SLC6A3 OPRM1 OPRK1 DRD3 DRD2
11 behavioral response to cocaine GO:0048148 10.06 OPRK1 DRD3 DRD2
12 synaptic transmission, cholinergic GO:0007271 10.06 CHRNB4 CHRNB3 CHRNA6 CHRNA5
13 prepulse inhibition GO:0060134 10.05 SLC6A3 DRD3 DRD2
14 sensory perception GO:0007600 10.04 OPRK1 OPRM1 PDYN
15 response to morphine GO:0043278 10.02 OPRM1 OPRK1 DRD3 DRD2
16 behavioral response to ethanol GO:0048149 10 OPRM1 DRD2 DBH
17 excitatory postsynaptic potential GO:0060079 10 CHRNA5 CHRNA6 CHRNB3 CHRNB4 DRD2 GABRA2
18 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.99 DRD3 DRD2
19 negative regulation of cytosolic calcium ion concentration GO:0051481 9.99 DRD3 DRD2
20 dopamine catabolic process GO:0042420 9.99 SLC6A3 DBH
21 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.99 DRD3 DRD2
22 G protein-coupled opioid receptor signaling pathway GO:0038003 9.98 OPRM1 OPRK1
23 behavioral response to nicotine GO:0035095 9.98 CHRNB4 CHRNA5
24 adenohypophysis development GO:0021984 9.98 SLC6A3 DRD2
25 serotonin uptake GO:0051610 9.97 SLC18A2 SLC6A4
26 hyaloid vascular plexus regression GO:1990384 9.97 DRD2 SLC6A3
27 monoamine transport GO:0015844 9.97 SLC6A4 SLC6A3 SLC18A2
28 response to nicotine GO:0035094 9.97 SLC6A3 DRD2 CHRNB4 CHRNB3 CHRNA5
29 dopamine uptake involved in synaptic transmission GO:0051583 9.96 SLC6A3 DRD2
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.96 DRD2 DRD3
31 dopamine transport GO:0015872 9.96 SLC18A2 SLC6A3
32 regulation of potassium ion transport GO:0043266 9.95 DRD2 DRD3
33 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.95 DRD2 DRD3
34 acid secretion GO:0046717 9.93 DRD3 DRD2
35 response to histamine GO:0034776 9.92 DRD3 DRD2
36 regulation of locomotion involved in locomotory behavior GO:0090325 9.92 DRD3 DRD2
37 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.91 OPRK1 OPRM1
38 response to cocaine GO:0042220 9.91 SLC6A3 OPRM1 OPRK1 DRD3 DRD2
39 regulation of postsynaptic membrane potential GO:0060078 9.85 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
40 regulation of synaptic vesicle exocytosis GO:2000300 9.84 DRD2 CHRNB3 CHRNA6 CHRNA5
41 locomotory behavior GO:0007626 9.8 SLC6A3 SLC18A2 OPRK1 DRD3 DRD2 DBH
42 presynaptic modulation of chemical synaptic transmission GO:0099171 9.73 DRD2 CHRNB3 CHRNA6 CHRNA5
43 regulation of biological quality GO:0065008 9.7 DRD3 DRD2
44 postsynaptic signal transduction GO:0098926 9.6 OPRK1 OPRM1
45 chemical synaptic transmission GO:0007268 9.58 SLC18A2 PDYN OPRK1 GABRA2 DBH CHRNB4

Molecular functions related to Cocaine Dependence according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 10.07 CHRNA5 CHRNA6 CHRNB3 CHRNB4 GABRA2
2 transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential GO:1904315 10.02 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
3 heterocyclic compound binding GO:1901363 9.93 CHRNB3 DRD2 SLC6A3
4 monoamine transmembrane transporter activity GO:0008504 9.91 SLC6A4 SLC6A3 SLC18A2
5 transmembrane signaling receptor activity GO:0004888 9.88 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
6 acetylcholine-gated monoatomic cation-selective channel activity GO:0022848 9.86 CHRNB4 CHRNB3 CHRNA6 CHRNA5
7 dopamine binding GO:0035240 9.85 SLC6A3 DRD2
8 serotonin:sodium:chloride symporter activity GO:0005335 9.81 SLC6A4 SLC18A2
9 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.8 DRD3 DRD2
10 monoatomic ion channel activity GO:0005216 9.8 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
11 acetylcholine receptor activity GO:0015464 9.76 CHRNA5 CHRNA6 CHRNB3 CHRNB4
12 G protein-coupled opioid receptor activity GO:0004985 9.71 OPRM1 OPRK1
13 excitatory extracellular ligand-gated monoatomic ion channel activity GO:0005231 9.65 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5
14 dopamine neurotransmitter receptor activity GO:0004952 9.52 DRD3 DRD2
15 extracellular ligand-gated monoatomic ion channel activity GO:0005230 9.02 GABRA2 CHRNB4 CHRNB3 CHRNA6 CHRNA5

Sources for Cocaine Dependence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....